Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02374788
Other study ID # SophiahemmetU
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2013
Est. completion date February 17, 2020

Study information

Verified date March 2020
Source Sophiahemmet University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to investigate the effects of two levels of primary care physical activity interventions on metabolic control and cardiovascular risk factors, compared to usual care in patients with pre- and type 2 diabetes.

The hypothesis is that both levels of interventions have effect on HbA1c with the more intense Group intervention having superior effects.


Description:

Regularly physical activity may decrease the risk for type 2 diabetes, cardiovascular diseases, overweight and premature deaths. Despite the evidence that physical activity is beneficial to health,it is often ignored and underused aspect in diabetes care. The aim of the study is to investigate the effects of two levels of primary care physical activity interventions on metabolic control and cardiovascular risk factors, compared to usual care in patients with pre- and type 2 diabetes.


Recruitment information / eligibility

Status Completed
Enrollment 188
Est. completion date February 17, 2020
Est. primary completion date February 17, 2020
Accepts healthy volunteers No
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria:

Ability to communicate in Swedish Age 40-80 years Type 2 diabetes: Diagnosed type 2 diabetes with a duration of >=1 year Pre-diabetes: HbA1c >39-<47, Fasting plasma glucose >5.6 mmol/l

Exclusion Criteria:

- Myocardial infarction in the past 6 months

- serum creatinine >140

- diabetic ulcer or risk for ulcer

- prescribed insulin in past 6 months

- additional disease prohibiting physical activity

- have experienced repeated hypoglycaemia or severe hypoglycaemia in past 12 months

- classified in very hard-intensity activity according to Stanford Brief Activity Survey

- having no access to internet.

Study Design


Intervention

Behavioral:
Pedometer intervention
Intensive intervention with pedometer. The participants are instructed to set daily step goal and to record their daily steps on a website.
Group meetings
Participants receive 12 group meetings over two years' time.
Individual consultations
Participants receive 10 individual meetings with a diabetes specialist nurse. Physical activity on prescription is used to set individual goals and to highlight the importance of physical activity.

Locations

Country Name City State
Sweden Sophiahemmet University Stockholm

Sponsors (4)

Lead Sponsor Collaborator
Sophiahemmet University Arizona State University, Karolinska Institutet, Uppsala University

Country where clinical trial is conducted

Sweden, 

References & Publications (1)

Rossen J, Yngve A, Hagströmer M, Brismar K, Ainsworth BE, Iskull C, Möller P, Johansson UB. Physical activity promotion in the primary care setting in pre- and type 2 diabetes - the Sophia step study, an RCT. BMC Public Health. 2015 Jul 12;15:647. doi: 10.1186/s12889-015-1941-9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Change in Dietary habits Change in Dietary habits is measured by a set of questions developed and validated by The Swedish National Food Agency. Evaluation is conducted at baseline and at week 8, 12, 24 and month 12 and 24 after completion of the intervention period
Other Change in Alcohol habits Change in Alcohol habits is measured by two questions from AUDIT-The alcohol Use disorders Evaluation is conducted at baseline and at week 24 and month 12 and 24 after completion of the intervention period
Other Change in Stress and working condition Change in Stress and working condition is measured by four questions Evaluation is conducted at baseline and at week 12, 24 and month 12 and 24 after completion of the intervention period
Other EuroQol (EQ-5D) measured by EQ-5D assess components of health related QoL (HRQoL). EQ-5D includes measures related to mobility, hygiene, daily activities, pain/ discomfort and anxiety/depression. week 0, 12, 24 and month 12 and 24
Other Sleep Sleep is measured by two questions. One question on difficulties falling asleep and one question on sleep quality. Evaluation is conducted at baseline and at week 12, 24 and month 12 and 24 after completion of the intervention period
Other Self reported physical activity International Physical Activity Questionnaire (IPAQ) self-reported 7-item questionnaire to assess physical activity. week 0, 12, 24 and month 12 and 24
Other Self-efficacy for exercise The questionnaire Self-efficacy for exercise is a 5 item questionnaire and assess one´s confidence to continue exercising in different situations. week 0, 12, 24 and month 12 and 24
Other Physical Activity Social Support (PASS) Physical Activity Social Support (PASS) for exercise 6 items. week 0, 12, 24 and month 12 and 24
Other Change in Neighborhood Environment Change in Neighborhood Environment is measured by 17 questions about Walking Environment, Availability of healthy Foods, Safety and Social cohesion Evaluation is conducted at baseline and at week 12, 24 and month 12 and 24 after completion of the intervention period
Other Change in Perceived Stress Scale (PSS) Change in Perceived Stress is measured by the Perceived Stress Scale (PSS) which is a 14- items questionnaire. Evaluation is conducted at baseline and at week 12, 24 and month 12 and 24 after completion of the intervention period
Other Change in diabetes distress (PAID-20) Diabetes distress is measured by The Problem Areas in Diabetes questionnaire (Swe-PAID-20): This is a 20 items questionnaire Evaluation is conducted at baseline and at week 12, 24 and month 12 and 24 after completion of the intervention period
Other Hospital Anxiety and Depression Scale (HADS) HADS is a 14 item questionnaire and consists of two subscales depression and anxiety, with seven items each. week 0, 12, 24 and month 12 and 24
Primary HbA1c (mmol/mol) Haemoglobin A1c up to month 24.
Secondary fasting plasma glucose (mmol/L) Determined by a glucose oxidase method week 0, 12, 24, and month 9, 12, 18 and 24.
Secondary Physical activity level (counts/min) Actigraph accelerometer GT1M week 0 and month 6, 12, 18, 24
Secondary Steps/day Actigraph accelerometer GT1M week 0, 8, 12, 16, 24, and month 9, 12, 18 and 24.
Secondary fasting-Insulin (mU/l) Serum insulin concentrations are determined with RIA-kits purchased from Pharmacia & Upjohn, Stockholm. week 0, 12, 24, and month 12 and 24.
Secondary LDL (mmol/L) LDL is determined by using a homogeneous method (lowdensity lipoprotein) week 0, 12, 24, and month 12 and 24.
Secondary Total cholesterol (mmol/L) total Cholesterol is determined by using enzymatic method week 0, 12, 24, and month 12 and 24.
Secondary IGF BP1 (µg/L) insulin-like growth factor binding protein 1 week 0, 12, 24, and month 12 and 24.
Secondary Free fatty acids (mmol(L ) Samples are saved for later free fatty acid analyses. week 0, 12, 24, and month 12 and 24.
Secondary Triglycerides (mmol/L) Triglycerides is determined by using enzymatic method (Triglycerides) week 0, 12, 24, and month 12, 18 and 24.
Secondary HDL (mmol/L) HDL is determined by using a homogeneous method (lowdensity lipoprotein)(High-density lipoprotein) week 0, 12, 24, and month 12, 18 and 24.
Secondary ApoB (g/l) Apolipoprotein B is determined by using turbimetric method week 0, 24 and month 24.
Secondary ApoA1 (g/l) ApolipoproteinA1 is determined by using turbimetric method week 0, 24 and month 24.
Secondary C-peptide (pmol/l) C-peptid are determined by using immunometric method using two monoclonal antibodies and detection with electrochemiluminiscense using a Modular E system (Beckman Coulter, Inc.). week 0, 12, 24, and month 12 and 24.
Secondary BMI (kg/m2) Body mass index week 0,8, 12,16, 24, and month 9, 12, 18 and 24.
Secondary Weight (kg) Tanita digital scale (Model TBF- 300A, Arlington Heights, IL). Weight is measured with light clothes, no shoes to the nearest 0.1 kg. week 0,8, 12,16, 24, and month 9, 12, 18 and 24.
Secondary % Body Fat % Body Fat is determined by Tanita digital scale (Model TBF- 300A, Arlington Heights, IL). week 0,8, 12,16, 24, and month 9, 12, 18 and 24.
Secondary Waist circumference (cm) Waist circumference is measured with SECA 201 tape, horizontal around the waist 2 cm above the umbilicus. week 0,8, 12,16, 24, and month 9, 12, 18 and 24.
Secondary Sagittal Abdominal Diameter (cm) Sagittal abdominal diameter is measured with the subject in a supine position with the knees expanded at the level of the umbilicus using a Holtain-Kahn abdominal caliper (Holtain, Ltd., Crosswell, Crymych; Dyfed, UK). week 0,8, 12,16, 24, and month 9, 12, 18 and 24.
Secondary Resting blood pressure (mmHg) diastolic blood pressure and systolic blood pressure. Resting blood pressure is measured with Omron M6 Comfort. week 0,8, 12,16, 24, and month 9, 12, 18 and 24.
Secondary Muscle strength measured by hand-held dynamometry. Hand grip strength is measured in kilograms using the hand-held Saehan Hydraulic Hand Dynamometer, model SH5001 (former Jamar) (Saehan Corporation, Masan, South Korea). week 0, 12, 24, and month 9, 12, 18 and 24.
Secondary Change in Smoking and snuffing habits Change in Smoking and snuffing habits is measured with questions on current and previous habits and the dose Evaluation is conducted at baseline and at 24 months after completion of the intervention period
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A

External Links